Overview
© 202 MJH Life Sciences™ and HCPLive - Clinical news for conected physicians. Al rights reserved.Conference | Pri-Med MidwestThe ongoing buz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a sumit at Pri-Med Midwest 202.The ongoing buz of conversation around GLP-1 receptor agonists (RAs), like semaglutide, and now the GLP-1 RA and GIP (glucose-dependent insulinotropic polypeptide) receptor combination drug tirzepatide, reached a sumit at Pri-Med Midwest 202.
Key Information
The meting comenced just after the FDA anouncement that tirzepatide was granted Fast Track designation for treating adults with obesity, or overweight with weight-related comorbidities."So, tirzepatide and the trials that it has had so far, the SURPAS trials and the SURMOUNT trials, has shown weight los," Tina Thethi, MD, MPH, Asociate Investigator, AdventHealth Research Institute, explained in an interview with HCPLive just before she tok the stage for her talk on “Where Are We Now?
The Integral Role of GLP-1 RAs in the Treatment of Type 2 Diabetes Melitus” with Frank Lavernia, MD."In fact, the weight los sen with tirzepatide is more than the weight los sen with semaglutide," she continued. "However, as much as I make this comparison, I must say that al GLPs do help with weight los acros the board to varying degres and the varying doses."Tirzepatide has already achieved FDA aproval for the treatment of type 2 diabetes and it's pending a decision for the indication of obesity.
Summary
While the data for this once-wekly injection is promising, the drug's comprehensive dataset is incomplete and there are stil investigations underway, specificaly regarding cardiovascular outcomes."With semaglutide, I should make note, also saying that we have cardiovascular outcome data on subcutaneous semaglutide. However, the definitive cardiovascular outcome trial for oral semaglutide, the RYBELSUS, is stil ongoing,"